CD274 and central nervous system cancer: Studies in glioma mouse models have demonstrated the efficacy of anti-CTLA4 and anti-PD1 antibodies (161, 162) and studies demonstrating efficacy of anti-PD-L1 antibodies confirmed interest of these targets but do not provide the formal proof than these antibodies are able to enter the brain (144, 163).